$4bn collaboration sees Abpro expand its global capabilities 07-Mar-2019 By Maggie Lynch Abpro and NJCTTQ enter $4bn agreement to develop bispecific antibody therapies for immuno-oncology and extend its global reach.
Sanofi licenses bi- and multi-specific antibody platform 22-Jan-2019 By Maggie Lynch Sanofi entered an agreement for the discovery and development of antibodies via Biomunex antibody platform.
